Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Electromed, Inc. is a U.S.-based medical device company that designs, manufactures, markets, and distributes airway clearance devices used in the treatment of chronic pulmonary conditions. The company operates within the medical devices and respiratory care industries, focusing specifically on High Frequency Chest Wall Oscillation (HFCWO) therapy to assist patients in mobilizing and clearing airway secretions. Its products are primarily prescribed for patients with diseases such as cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease (COPD), and neuromuscular disorders that impair effective coughing.
Electromed’s core revenue driver is the SmartVest® Airway Clearance System, a portable HFCWO device sold primarily through physician prescription and reimbursed by private insurers, Medicare, and other government healthcare programs. The company is positioned as a niche, patient-focused provider emphasizing portability, ease of use, and in-home therapy. Founded in 1992, Electromed initially focused on electronic medical products before pivoting to respiratory therapy devices, gradually refining its technology and commercial strategy to concentrate on airway clearance solutions.
Business Operations
Electromed operates as a single-reportable-segment company centered on the development and commercialization of airway clearance therapy devices. Revenue is generated predominantly through direct sales of the SmartVest® system to patients, healthcare providers, and distributors, with a significant portion of sales occurring in the U.S. home healthcare market. The company manages its own sales force, reimbursement support services, and patient education programs, which are integral to navigating complex insurance approval processes.
Manufacturing and product assembly are conducted in the United States, and the company controls its proprietary HFCWO technology and related intellectual property. Electromed does not rely heavily on joint ventures but operates through wholly owned subsidiaries, including Electromed Ltd., which supports limited international distribution. The business model emphasizes recurring demand driven by chronic disease prevalence rather than consumable-based recurring revenue.
Strategic Position & Investments
Electromed’s strategy centers on organic growth through expanded physician outreach, increased insurance coverage penetration, and incremental product enhancements rather than large-scale acquisitions. The company continues to invest in clinical education, patient advocacy, and reimbursement infrastructure to strengthen its competitive position against larger respiratory device manufacturers. Its differentiation strategy focuses on device portability, patient comfort, and customer service.
Capital investments are primarily directed toward product development, manufacturing efficiency, and information systems supporting sales and reimbursement workflows. Electromed has historically maintained a conservative balance sheet, with limited acquisition activity and no major transformative mergers publicly disclosed. The company remains focused on the airway clearance niche and has not announced material diversification into unrelated medical device categories.
Geographic Footprint
Electromed is headquartered in the United States, with its principal executive offices and manufacturing operations located in Minnesota. The vast majority of revenue is generated domestically, reflecting the company’s strong dependence on U.S. healthcare reimbursement systems and physician-prescribed homecare therapies.
Internationally, Electromed has a limited footprint, with sales occurring in select markets through distributors and its wholly owned subsidiary Electromed Ltd. These international activities represent a relatively small portion of total revenue, and the company does not currently maintain large-scale manufacturing or sales operations outside North America.
Leadership & Governance
Electromed is led by an executive team with long-standing experience in medical devices, respiratory care, and healthcare commercialization. The leadership philosophy emphasizes disciplined growth, regulatory compliance, and patient-centered innovation, with strategic decisions guided by profitability, cash generation, and long-term market sustainability.
Key executives include:
- Jim Cunniff – Chief Executive Officer
- Andrew Summers – Chief Financial Officer
- Luke Porth – Vice President of Sales
- Lesa Linden – Vice President of Marketing
- Nathan Eide – Vice President of Operations
The company is publicly traded and governed by a board of directors responsible for oversight of strategy, risk management, and compliance with U.S. public company regulations, including periodic reporting under SEC filings such as Form 10-K and Form 10-Q.